Connection

Maria Lopes-Virella to Lipoproteins, LDL

Back to Details
This is a "connection" page, showing publications Maria Lopes-Virella has written about Lipoproteins, LDL.
Maria Lopes-Virella
Connection Strength
10.920
Lipoproteins, LDL
  1. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.534
  2. Modified LDL Immune Complexes and Cardiovascular Disease. Curr Med Chem. 2019; 26(9):1680-1692.
    View in: PubMed
    Score: 0.517
  3. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9.
    View in: PubMed
    Score: 0.466
  4. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54.
    View in: PubMed
    Score: 0.356
  5. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74.
    View in: PubMed
    Score: 0.341
  6. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
    View in: PubMed
    Score: 0.333
  7. Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III. Clin Immunol. 2011 Jun; 139(3):258-66.
    View in: PubMed
    Score: 0.299
  8. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011 Feb; 214(2):462-7.
    View in: PubMed
    Score: 0.294
  9. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011 Feb; 60(2):582-9.
    View in: PubMed
    Score: 0.293
  10. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
    View in: PubMed
    Score: 0.265
  11. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
    View in: PubMed
    Score: 0.248
  12. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009 Feb; 202(2):394-404.
    View in: PubMed
    Score: 0.248
  13. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006 Sep; 47(9):1975-83.
    View in: PubMed
    Score: 0.217
  14. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005 Jan; 12(1):68-75.
    View in: PubMed
    Score: 0.196
  15. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
    View in: PubMed
    Score: 0.190
  16. Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells. J Lipid Res. 2004 May; 45(5):873-80.
    View in: PubMed
    Score: 0.184
  17. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505.
    View in: PubMed
    Score: 0.176
  18. LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1. J Lipid Res. 2003 Jul; 44(7):1315-21.
    View in: PubMed
    Score: 0.174
  19. Humoral immunity and atherosclerosis. Nat Med. 2003 Mar; 9(3):243-4; author reply 244-5.
    View in: PubMed
    Score: 0.172
  20. Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins. J Clin Lipidol. 2022 Mar-Apr; 16(2):173-183.
    View in: PubMed
    Score: 0.159
  21. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis. 2001 May; 156(1):119-25.
    View in: PubMed
    Score: 0.152
  22. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis. 2001 Jan; 154(1):79-86.
    View in: PubMed
    Score: 0.148
  23. Effect of inflammatory cytokines on the metabolism of low-density lipoproteins by human vascular endothelial cells. Metabolism. 2001 Jan; 50(1):99-106.
    View in: PubMed
    Score: 0.148
  24. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res. 2000 Dec; 41(12):2017-23.
    View in: PubMed
    Score: 0.148
  25. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2000 Dec; 20(12):2533-8.
    View in: PubMed
    Score: 0.148
  26. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis. 2000 Sep; 152(1):107-15.
    View in: PubMed
    Score: 0.145
  27. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.143
  28. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000 May; 95(2):135-44.
    View in: PubMed
    Score: 0.142
  29. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Nov; 19(11):2640-7.
    View in: PubMed
    Score: 0.137
  30. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999 Jul; 48(7):1454-8.
    View in: PubMed
    Score: 0.134
  31. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol. 1999 Jul; 19(7):1600-7.
    View in: PubMed
    Score: 0.134
  32. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
    View in: PubMed
    Score: 0.130
  33. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. Arch Pediatr Adolesc Med. 1999 Jan; 153(1):57-62.
    View in: PubMed
    Score: 0.129
  34. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997 Dec; 135(2):161-70.
    View in: PubMed
    Score: 0.120
  35. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82.
    View in: PubMed
    Score: 0.118
  36. Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes. J Lipid Res. 1997 Jan; 38(1):110-20.
    View in: PubMed
    Score: 0.113
  37. F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016 Dec; 173:50-56.
    View in: PubMed
    Score: 0.109
  38. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996 Jul; 45 Suppl 3:S40-4.
    View in: PubMed
    Score: 0.109
  39. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996 Jun; 45(6):762-7.
    View in: PubMed
    Score: 0.108
  40. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996 Feb; 16(2):222-9.
    View in: PubMed
    Score: 0.106
  41. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
    View in: PubMed
    Score: 0.105
  42. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.104
  43. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 1995 Sep; 44(9):1093-8.
    View in: PubMed
    Score: 0.103
  44. Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopathol. 1995 May; 75(2):179-89.
    View in: PubMed
    Score: 0.100
  45. Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 1995 Feb; 41(2):324-5.
    View in: PubMed
    Score: 0.099
  46. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014 May; 55(5):860-9.
    View in: PubMed
    Score: 0.093
  47. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22.
    View in: PubMed
    Score: 0.090
  48. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993; 23(2):95-101.
    View in: PubMed
    Score: 0.085
  49. Influence of glycemic control on interaction of very-low- and low-density lipoproteins isolated from type I diabetic patients with human monocyte-derived macrophages. Diabetes. 1992 Oct; 41(10):1301-7.
    View in: PubMed
    Score: 0.084
  50. Lipoprotein-immune complexes and diabetic vascular complications. Diabetes. 1992 Oct; 41 Suppl 2:92-6.
    View in: PubMed
    Score: 0.084
  51. Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology. 2012 May; 136(1):30-45.
    View in: PubMed
    Score: 0.081
  52. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
    View in: PubMed
    Score: 0.081
  53. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1356-67.
    View in: PubMed
    Score: 0.078
  54. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.078
  55. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991 Apr; 59(1):37-52.
    View in: PubMed
    Score: 0.075
  56. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010 Sep 02; 5(9).
    View in: PubMed
    Score: 0.073
  57. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.071
  58. Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages. Diabetologia. 1990 May; 33(5):299-305.
    View in: PubMed
    Score: 0.071
  59. Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010 May 21; 285(21):15985-93.
    View in: PubMed
    Score: 0.070
  60. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7.
    View in: PubMed
    Score: 0.064
  61. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988 May; 37(5):550-7.
    View in: PubMed
    Score: 0.062
  62. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 Oct; 200(2):239-46.
    View in: PubMed
    Score: 0.061
  63. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987 Dec; 30(12):916-23.
    View in: PubMed
    Score: 0.060
  64. Low density lipoprotein metabolism in human macrophages stimulated with microbial or microbial-related products. Arteriosclerosis. 1987 Mar-Apr; 7(2):176-84.
    View in: PubMed
    Score: 0.057
  65. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9.
    View in: PubMed
    Score: 0.055
  66. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.053
  67. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat. 2006 Mar; 79(1-2):126-40.
    View in: PubMed
    Score: 0.053
  68. Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85.
    View in: PubMed
    Score: 0.052
  69. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78.
    View in: PubMed
    Score: 0.050
  70. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism. 2005 Apr; 54(4):453-9.
    View in: PubMed
    Score: 0.050
  71. Abnormal metabolism of low density lipoprotein in diabetes mellitus. Horm Metab Res Suppl. 1985; 15:83-7.
    View in: PubMed
    Score: 0.049
  72. Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Diabetes. 1983 Jan; 32(1):20-5.
    View in: PubMed
    Score: 0.043
  73. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
    View in: PubMed
    Score: 0.042
  74. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct; 105(1):81-92.
    View in: PubMed
    Score: 0.042
  75. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6.
    View in: PubMed
    Score: 0.041
  76. Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol. 1998 Nov; 5(6):817-22.
    View in: PubMed
    Score: 0.032
  77. Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro. Am J Physiol Endocrinol Metab. 2018 11 01; 315(5):E745-E757.
    View in: PubMed
    Score: 0.031
  78. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J. 1993 Dec; 14 Suppl K:118-24.
    View in: PubMed
    Score: 0.023
  79. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes. 1992 Oct; 41 Suppl 2:86-91.
    View in: PubMed
    Score: 0.021
  80. Reducing vascular disease risk in the type 2 diabetic patient. J Clin Lipidol. 2011 Jan-Feb; 5(1):3-11.
    View in: PubMed
    Score: 0.018
  81. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988 Sep 01; 168(3):1041-59.
    View in: PubMed
    Score: 0.016
  82. Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control. Diabetologia. 1981 Sep; 21(3):216-23.
    View in: PubMed
    Score: 0.010
  83. Quercetin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells through extracellular signal-regulated kinase. Arch Biochem Biophys. 2001 Jul 01; 391(1):72-8.
    View in: PubMed
    Score: 0.010
  84. Serum high density lipoprotein in diabetic patients. Diabetologia. 1977 Aug; 13(4):285-91.
    View in: PubMed
    Score: 0.007
  85. Platelet lipoproteins. A comparative study with serum lipoproteins. Biochim Biophys Acta. 1976 Aug 09; 439(2):339-48.
    View in: PubMed
    Score: 0.007
  86. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983 Nov 30; 75(5B):67-80.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.